Results 181 to 190 of about 42,521 (302)

Systemic Pharmacokinetic Principles of Therapeutic Peptides. [PDF]

Clin Pharmacokinet
Nordell P, Jansson-Löfmark R, Gennemark P.   +2 more
europepmc   +1 more source

Cardiovascular Disease and Obesity Medications in Older Women by Obesity‐Related Cancers Status: SEER‐Medicare 2007–2015

Obesity, EarlyView.
ABSTRACT Objective This study evaluated the association between antiobesity medications (AOM) and incident cardiovascular disease (CVD) among older women, examining this relationship within and across survivors of obesity‐related cancers (ORCa) and age‐matched cancer‐free populations.
David S. Lopez, Omer Abdelgadir, Yuanyi Zhang, Jesús Gibran Hernández‐Pérez, Maryam R. Hussain, Mohanad Albayyaa, Rasmi Nair, Yong‐Fang Kuo, Jaime P. Almandoz, Lindsay G. Cowell, Sarah E. Messiah   +10 more
wiley   +1 more source

Selection for Molecularly Complementary Modules (MCMs) Drives the Origins and Evolution of Pleiofunctional, Epistatic Interactomes (PEIs). [PDF]

Life (Basel)
Root-Bernstein R.
europepmc   +1 more source

Monogenic and syndromic obesity in children: Clinical recognition, genetics, and precision management

Pediatric Investigation, EarlyView.
Monogenic and syndromic obesity in children often arises from defects in the leptin–melanocortin pathway. Understanding these rare genetic causes not only clarifies mechanisms of appetite regulation but also enables precision therapies, offering hope beyond lifestyle interventions.
Hadel Khalil, Eugene Feigin, Hussein Zaitoon   +2 more
wiley   +1 more source

In Vitro Evaluation of ACE and DPP-IV Inhibitory, and GLP-1 Stimulation Activities of Collagen Hydrolysate Enriched in Tripeptides. [PDF]

Biomedicines
Fanzaga M, d'Adduzio L, Bollati C, Musco MS, Boschin G, Aiello G, Lammi C.   +6 more
europepmc   +1 more source

Fast Quantitative Evaluation of the Amelioration Effect in MASLD During Semaglutide Treatment Using Ultrasound‐Derived Fat Fraction and Fat‐to‐Muscle Ratio

Portal Hypertension &Cirrhosis, EarlyView.
Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a chronic liver disease. Research into a feasible, rapid, and effective assessment method is crucial for evaluating the therapeutic effects of semaglutide in MASLD. This prospective study utilized ultrasound‐derived fat fraction measurement and fat‐to‐muscle ratio to evaluate hepatic ...
Yunlin Huang, Ruping Yang, Ying Wang, Xiu‐Yun Lu, Li Wei, Rui Cheng, Juan Cheng, Yijie Qiu, Shiwen Wang, Bo Li, Yi Dong   +10 more
wiley   +1 more source

Incretin Analogues for Weight Reduction in Non-Diabetic Obese: A Review of Liraglutide, Semaglutide, and Tirzepatide Beyond Glycemic Control. [PDF]

Rambam Maimonides Med J
Bonga KN, Padhan M.
europepmc   +1 more source

Ülseratif kolitli hastalarda `glucagon like peptide-1` ve `glucagon like peptide-2` düzeyleri

, 2020
Giriş-Amaç: Ülseratif kolit hastalığı barsağın kronik inflamatuvar bir hastalığıdır. ?Glucagon like peptide-1? barsak enteroendokrin L hücrelerinden salgılanan ve kan şekerinin düzenlenmesinde görevli bir peptiddir. ?Glucagon like peptide-2? de barsak enteroendokrin L hücrelerinden salgılanır ve barsak mukoza bütünlüğünün korunmasında görevlidir ...
openaire   +1 more source

From HBV to MASLD Cirrhosis: Mechanistic Insights and Therapeutic Strategies

Portal Hypertension &Cirrhosis, EarlyView.
This review examines the epidemiological shift from hepatitis B virus (HBV) to metabolic dysfunction‐associated steatotic liver disease (MASLD) as the leading cause of cirrhosis globally. It highlights the distinct pathogenic mechanisms between HBV and MASLD cirrhosis and discusses evolving diagnostic tools and therapeutic strategies tailored to the ...
Hanqi Yu, Hongfan Ding, Yang Huang, Haoze Cao, Yuan Ding, Weilin Wang   +5 more
wiley   +1 more source

Glucagon-like Peptide-1 Receptor Agonists and Platelet Function: Potential Benefits Beyond Glycemic Control. [PDF]

Pharmaceuticals (Basel)
Xanthopoulou M, Evangelidis P, Poulis D, Gavriilaki E, Kotsiou N, Antza C, Kotsis V, Doxani C, Mprotsis T, Zintzaras E, Anyfanti P.   +10 more
europepmc   +1 more source